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Abstract In forensic pathology routine, fatal cases of contrast
agent exposure can be occasionally encountered. In such
situations, beyond the difficulties inherent in establishing the
cause of death due to nonspecific or absent autopsy and
histology findings as well as limited laboratory investigations,
pathologists may face other problems in formulating exhaus-
tive, complete reports, and conclusions that are scientifically
accurate. Indeed, terminology concerning adverse drug reac-
tions and allergy nomenclature is confusing. Some terms, still
utilized in forensic and radiological reports, are outdated and
should be avoided. Additionally, not all forensic pathologists
master contrast material classification and pathogenesis of
contrast agent reactions. We present a review of the literature
covering allergic reactions to contrast material exposure in
order to update used terminology, explain the pathophysiolo-
gy, and list currently available laboratory investigations for
diagnosis in the forensic setting.
Keywords Allergic reactions . Adverse drug reactions .
Contrast material . Mast cells . Anaphylaxis .β-tryptase
Introduction
Adverse drug reactions are relatively frequent in clinical prac-
tice and can be responsible for serious health problems. The
most common are correlated to a known pharmacologic or
toxic drug property, are predictable and may occur in anyone.
Less common adverse reactions, which include allergy, do not
depend on the pharmacologic property of the drug and may
occur in people with a certain predisposition. These reactions
are therefore unpredictable [1, 2].
Several drugs have been implicated as causing adverse reac-
tions, some potentially life-threatening. Reactions to
radiocontrast media, magnetic resonance imaging (MRI) contrast
agents, and contrast material used in neurosurgery as well as
ophthalmic surgery represent a portion of adverse drug reactions.
In the medicolegal setting, fatal cases of contrast agent
exposure can be occasionally encountered. In these situations,
beyond the classical problems inherent in establishing the
cause of death that are related to nonspecific or absent mac-
roscopic and microscopic findings as well as limited, reliable
laboratory investigation tools, forensic pathologists may face
difficulties in formulating exhaustive reports and conclusions.
Indeed, numerous fatal and nonfatal cases of adverse reac-
tions to contrast material exposure have been described in
radiological and medicolegal literature. However, the terms
that appear in different reports are often used interchangeably
though they should not be. Though still utilized in some
circumstances, some terms (pseudoallergic, anaphylactoid,
etc.) are outdated and should be avoided. In addition, not all
forensic pathologists are at ease with contrast agent terminol-
ogy. This makes the elaboration of reports on autopsy even
more challenging since they must be understandable for the
inquiring authorities, precise regarding used terminology, and
scientifically unobjectionable at the same time.
The aim of this article was to examine the radiological and
medicolegal literature pertaining to adverse reactions to con-
trast material exposure in order to shed light on classification,
pathophysiology, and postmortem diagnosis of reactions to
contrast material.
Adverse drug reaction and allergy nomenclature
Adverse drug reactions are broadly categorized into predictable
and unpredictable. Predictable reactions are usually dose-
dependent, are related to the known pharmacologic actions of
the drug, and occur in otherwise healthy individuals. They are
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subdivided into overdoses, side effects, secondary ef-
fects, and drug interactions. Unpredictable reactions are
generally dose independent, are unrelated to the phar-
macologic actions of the molecule, and occur in suscep-
tible subjects only. They are subdivided into drug intol-
erance, drug idiosyncrasy, and drug allergy or immuno-
logic reactions. Unpredictable reactions also include
pseudoallergic reactions, also called anaphylactoid reactions,
which are due to the direct release of mediators from mast
cells and basophils. However, theWorld Allergy Organization
has proposed that reactions without an immunologic mecha-
nism be referred as nonallergic reactions and that the terms
pseudoallergic and anaphylactoid no longer be used [1–6].
A consensus statement from the World Allergy
Organization clarified the classification of allergic and
nonallergic drug reactions based on the mechanism initiating
the inflammatory reaction causing symptoms and signs.
According to the revised nomenclature, the term hypersen-
sitivity should be used to describe objectively reproducible
symptoms or signs initiated by exposure to a defined stimulus
at a dose tolerated by normal persons.
Allergy is a hypersensitivity reaction initiated by specific
immunologic mechanisms . When other mechanisms can be
proven, the term nonallergic hypersensitivity should be used.
Allergy can be antibody-mediated or cell-mediated . In
most patients with allergic symptoms from mucosal mem-
branes in the airways and gastrointestinal tract, the antibodies
belong to the IgE isotype and these patients may be said to
have an IgE-mediated allergy. IgE in this context refers to IgE
antibodies to an allergen. An allergen is an antigen causing
allergic disease.
In non-IgE-mediated allergy, the inflammation involves
allergen-specific lymphocytes , as in allergic contact dermatitis
or antibodies of the IgG isotype .
On the basis of these definitions, the appropriate term for
food hypersensitivity is food allergy when immunologic
mechanisms have been demonstrated. Food-specific IgG an-
tibodies in serum are not of clinical importance but merely
indicate previous exposure to the food. If IgE is involved in
the reaction, the term IgE-mediated food allergy is appropri-
ate. Other reactions should be referred to as nonallergic food
hypersensitivity.
Likewise, when immunologic mechanisms, either antibody
or cell-mediated, have been demonstrated, reactions should be
referred to as drug allergy. Adding the adjectives im-
mediate or delayed , both describes the onset of symp-
toms and indicates the probable immunological mecha-
nism involved, i.e., IgE or lymphocyte cell-mediated,
respectively. IgE-mediated drug allergy represents a smaller
fraction of drug hypersensitivity.
Lastly, insect venom and saliva hypersensitivity mediated
by an immunologic mechanism should be referred to as ven-
om or saliva allergy, as in bee venom allergy.
The term anaphylaxis is used differently by physicians
throughout the world. It has been proposed that anaphylaxis
is the umbrella term for an acute reaction defined as follows:
anaphylaxis is a severe, life-threatening generalized or sys-
temic hypersensitivity reaction . The term allergic anaphylaxis
should be used when the reaction is mediated by an immuno-
logic mechanism, e.g., IgE or immune complexes. An ana-
phylactic reaction mediated by IgE antibodies, such as peanut-
induced food anaphylaxis, may be referred to as IgE-mediated
allergic anaphylaxis . Conversely, anaphylaxis from any
nonimmunologic cause should be referred to as nonallergic
anaphylaxis [2, 7, 8].
Immune response mechanisms
Drug allergies are mediated by the immune system. However,
it is often difficult to differentiate between immune- and
nonimmune-mediated adverse drug reactions. Since the clin-
ical signs and symptoms of most immune reactions are ob-
served only in the elicitation phase and not in the preceding
sensitization phase, the dogma has been that allergy to drugs
are only observed on re-exposure or longer-lasting exposure
to the drug. However, more recent data has shown that previ-
ous contact with the causative drug is not a prerequisite for
immune-mediated drug hypersensitivity. These findings indi-
cate that the paradigm must be changed, and that drug aller-
gies might be best explained by cross-reactivity between the
drug involved and other molecules to which the affected
subject may have been previously exposed.
The sensitization phase primarily involves stimulation and
expansion of drug-specific lymphocytes. This may affect T
cells alone or both T cells and B cells, with consequent
formation of drug-specific antibodies (mostly IgE).
Drug molecules and their metabolites are too small to elicit
an immune response by themselves. Thus, to be immunogen-
ic, they are thought to act as haptens or prohaptens. Haptens
are chemically reactive, small molecules that covalently bind
to a larger protein or peptide. Prohaptens are inert drugs that
undergo metabolism (bioactivation) and become reactive me-
tabolites (haptens), which can then bind covalently to a protein
that acts as a carrier.
In addition to drug- and drug metabolite-carrier complexes,
drug-independent cross-reactive antigens can also induce sen-
sitization. This phenomenon of immunologic cross-reactivity
occurs when an immune response to one antigen results in
reactivity to structurally related antigens. Cross-reactivity me-
diated by immunologic mechanisms is usually explained by
the presence of a common antigenic determinant in cross-
reacting drugs. Cross-reactivity can also derive from
nonspecific binding of drugs to IgE on the surface of mast
cells and basophils. Most cross-reactivity syndromes are
thought to be due to IgE antibodies. However, there is also
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support for T cell-mediated cross-reactivity, independent of
IgE-mediated mechanisms [1, 9–11].
After primary sensitization to a causative drug, renewed
contact with the antigen may induce the elicitation phase,
corresponding to type I to IV immune reactions (Gell and
Coombs classification). Most commonly observed drug aller-
gies are type I or IV reactions, whereas type II and III are
encountered infrequently.
Type I reactions are based on IgE-mediated hypersensitiv-
ity. The soluble IgE produced by B cells circulates and binds
to the receptor located on the surface of mast cells and baso-
phils. Mast cells are tissue-resident cells that can be found in
the skin, gut, and respiratory tract as well as adjacent to nerves
and blood vessels. Among their most important immune func-
tions is the propensity to bind circulating IgE utilizing the
high-affinity IgE receptor. When an allergen is re-encountered
and recognized by IgE antibodies bound to mast cell surface,
the activated mast cell undergoes degranulation. The immedi-
ate liberation of preformed mediators such as histamine,
tryptase, chymase, carboxypeptidase, cathepsin G, and hepa-
rin elicits the acute symptoms of type I hypersensitivity reac-
tions in the skin, gut, respiratory, and cardiovascular systems.
These symptoms typically begin within minutes of antigen
exposure. Serum tryptase is not uniformly elevated in food
allergy, leading some to question whether basophils play a
larger role thanmast cells do in human food allergy. Mast cells
also synthesize other mediators such as leukotrienes and pros-
taglandins upon activation, requiring several hours to achieve
their inflammatory effects, including recruitment and activa-
tion of secondary immune cells such as eosinophils.
Delayed hypersensitivity type IV reactions are mediated by
cellular immune mechanisms and may have a variety of
clinical manifestations ranging from skin involvement alone
to fulminant systemic diseases. A recently proposed modifi-
cation subdivides type IV reactions into four categories in-
volving activation and recruitment of monocytes (IVa), eosin-
ophils (IVb), CD4+ or CD8+ T cells (IVc), and neutrophils
(IVd). The classic reaction in hypersensitivity type IV is
contact dermatitis [1, 4, 9, 12–16].
Contrast medium classification andmechanism of adverse
reactions
Iodinated radiocontrast media are among the most commonly
used contrast agents in radiology. They are subdivided into
ionic monomer, ionic dimmer, nonionic monomer, and non-
ionic dimmer.
Additionally, iodinated contrast agents can be classified by
their osmolality relative to blood and are typically described as
high, low, and iso-osmolar.
Modern radiocontrast agents can be used almost every-
where in the body. Most often they are used intravenously
though they can be administered intra-arterially, intrathecally,
and intra-abdominally.
Iodine is the element used in radiocontrast media as it
possesses important properties essential for the production of
contrast, including high-contrast density and low toxicity.
Contrast agents are also used in MRI though these are not
made of iodine. Currently, available MRI contrast agents can
be classified in various ways according to their various fea-
tures, such as the presence and nature of their metal center and
their magnetic properties (paramagnetic or superparamagnetic
agents). Regarding the metal center, the simplest one is a
single paramagnetic ion bound to an organic ligand in a
chelate. The paramagnetic ion is usually gadolinium (Gd3+)
or manganese (Mn2+), and the most common ligands are
linear or macrocyclic polyaminocarboxylate/phosphonate de-
rivatives. Most contrast-enhancedMRI procedures worldwide
are performed with MRI contrast agents based on chelates of
the paramagnetic ion gadolinium [17–20].
Although their frequency is low, adverse reactions to con-
trast agents in general, and allergic reactions in particular, are
responsible for relevant morbidity and may quickly become
life-threatening. Iodinated contrast media, gadolinium-based
contrast agents, microbubbles used as ultrasound contrast
agents and contrast material used in ophthalmic surgery are
all able to induce adverse reactions that can either be allergic
or nonallergic and may be either immediate or delayed [21].
Katayama et al. [22] found that 70 % of adverse reactions to
iodinated contrast media occurred within the first 5 min follow-
ing contrast material injection. Whereas immediate reactions
occur within 1 h of administration, delayed adverse reactions
are defined as reactions occurring from 1 h up to 10 days after
contrast material administration. Skin reactions including
maculopapular rashes, erythema, swelling, and pruritus are com-
mon and account for most delayed hypersensitivity reactions.
Most skin reactions are mild or moderate, self-limiting, and
involve T cell-mediated mechanisms. Acute life-threatening or
fatal reactions to iodinated contrast media may occur following
intravenous or intra-arterial injection but may also develop after
alimentary or intracavitary administration due to the absorption
of iodinated contrast material particles into circulation [23].
The mechanisms of immediate reactions to iodinated con-
trast media are still a matter of speculation. There is some
indirect evidence that they may be caused by an IgE-mediated
mechanism. Indeed, immediate reactions to radiocontrast me-
dia are associated with histamine and other mediator release
from basophils and mast cells. Additionally, it has been dem-
onstrated that patients with hypersensitivity reactions after
radiocontrast agent exposure had increased plasma levels of
both histamine and tryptase. Furthermore, the levels of both
molecules correlated with the severity of the reaction.
However, nonimmunologic mechanisms have also been
postulated. Symptoms of nonallergic reactions to
radiocontrast material are caused by histamine release from
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mast cells and basophils either directly by a membrane effect
possibly related to the osmolality of the contrast material
solution or the nonspecific binding of contrast material mole-
cules on membrane IgE or indirectly by an activation of the
complement system and a bradykinin-induced mechanism. In
vitro and in vivo evidence is provided, indicating that both
ionic and nonionic contrast media activate plasma kallikrein
with consecutive factor XII contact phase activation as well as
stimulation of the bradykinin generation. Furthermore, activa-
tion of the complement cascade via classic and alternative
pathways was described to some extent for intravascular ap-
plication of contrast agents. In nonreactors, these alterations
are transient and have only a limited extent, indicating that
these reactions are within the regulatory capacity of the kalli-
krein–kinin–factor XII system. In reactors, however, signifi-
cant evidence for extended kallikrein system activation is
associated with reduced C1-esterase inhibitor levels.
Therefore, individuals with alterations in these systems could
be regarded as candidates for nonimmunologic, adverse reac-
tions to contrast agents [24–27].
An important argument against the immunologic mecha-
nism is that patients can react to contrast media on first exposure
and that reactions do not always occur. It has been proposed that
previously non-exposed patients might have already been sen-
sitized, though the molecules responsible for the sensitization
remain unknown. Various factors favor a nonallergic mecha-
nism in these cases. These factors include that contrast media
are small-sized molecules thereby necessitating haptenization
to become immunogenic, that patients can react on initial
exposure, that contrast material-specific IgE antibodies are not
systematically detected in patient serum, and that positive skin
tests can be found in only a minority of subjects. Furthermore,
the affinity of IgE to a contrast agent is extremely low and
suggests a nonspecific rather than specific binding, the latter
occurring only at high concentrations of the compound [11].
On the other hand, however, the positive skin tests in some
individuals as well as the detection of contrast material-
specific IgE antibodies reported by some investigators in a
fraction of patients support the concept that the IgE-mediated
mechanismmay be one of the possible mechanisms, at least in
a portion of these patients. More recent research has described
positive skin tests with cross-reactivity to similar radiocontrast
material in patients who reported a radiocontrast material
allergy. T cell cross-reactivity between various radiocontrast
agents has also been described in some patients with delayed
hypersensitivity reactions [2, 11, 28, 29].
Immediate reactions have been reported in association with
intravenous administration of gadolinium-based contrast
agents. The pathophysiologic mechanisms, however, are not
completely understood. Based on positive skin tests to the
contrast material that caused the reaction, some reports sug-
gested an IgE-mediated mechanism. However, it is still
unclear whether polysensitization and cross-reaction exist
within similar molecules. Another report suggesting an im-
munologic mechanism showed that the risk of immediate
hypersensitivity reactions to gadolinium-based contrast media
was up to eight times higher in patients who had had previous
reactions to gadolinium-based contrast agents, with the second
reaction tending to be more pronounced than the first [30, 31].
However, Kun and Jakubowski [20] demonstrated that ionic
and nonionic preparations ofMRI contrast agents were able to
directly induce mast cell degranulation in vitro, suggesting
that the mechanism (or one of the mechanisms) responsible
for mast cell degranulation belong to the group of IgE-
independent reactions.
Sodium fluorescein and 5-aminolevulinc acid are the most
common fluorescent dyes used in brain tumor surgery. The
exact pathogenesis of adverse reactions to fluorescein is still
unknown andmay bemultiple. An immunologic, IgE-mediated
mechanism has been proposed to explain fluorescein-induced
hypersensitivity reactions in both ophthalmic and neurosurgery
cases. However, an argument against the allergic nature of the
reaction is that patients can react to fluorescein on first expo-
sure. In these cases, the chemical structures and route respon-
sible for the sensitization are unknown. An allergy history of
drug and/or food has been identified as one of the major risk
factors for adverse reaction during fluorescein angiography.
However, nonimmunologic reactions are now believed to be
themain type of reaction foundwith intravenous, oral, and even
topical fluorescein. Amarked reduction in reactions was report-
ed after oral fluorescein administration, though adverse reac-
tions can still occur [32].
Severe reactions following indocyanine green injection for
angiography were described in ophthalmic literature and two
deaths were reported with nonophthalmic use of indocyanine
green. Though both terms, “anaphylactic” and “anaphylac-
toid,” are mentioned in these reports, an immunologic mech-
anism was not proven and dependency on the applied dose
was also postulated [33–40].
IgE-mediated and non-IgE-mediated immunologic reac-
tions were described in association with patent blue Vadmin-
istration used in the identification of sentinel lymph nodes
during staging procedures in patients with breast cancer and
other malignancies. Allergic reactions during sentinel lymph
node biopsy in breast cancer have also been reported with
isosulfan blue. Adverse reactions related to echocardiographic
contrast agent use (intravenous succinylated gelatin
(Gelofusine) during transthoracic echo bubble study, intrave-
nous perfluoropropane gas in lipid microbubbles (Perflutren)
during contrast echocardiography, and intravenous sulphur
hexafluoride (Sonovue) during contrast echocardiography)
are mentioned in the literature as “severe anaphylaxis,” “he-
modynamic instability,” and “anaphylactic shock,” respec-
tively. Adverse reactions to succinylated gelatin and other
plasma expanders are well described. Pathogenesis is unclear,
and both IgE and non-IgE mechanisms have been proposed.
98 Int J Legal Med (2014) 128:95–103
Conversely, an immunologic mechanism explaining an ad-
verse reaction to perfluoropropane and sulphur hexafluoride
was not demonstrated [41–48].
Markers of mast cell activation
Mast cells are the primary effector cells of immediate hyper-
sensitivity reactions. Activated mast cells release both
preformed and newly synthesized mediators. The former in-
clude histamine, heparin, and several proteases such as tryptase,
chymase, mast cell carboxypeptidase, and cathepsin G. The
latter include lipid mediators such as prostaglandin D(2) and
leukotriene C(4) as well as cytokines and interleukins.
β-tryptase is the main protease in all mast cells, although
basophils also contain trace amounts. Currently, only mast cells
and basophils have been shown to express tryptase mRNA.
Many of these mediator are stored in cytoplasmic granules,
and their release may be induced by (a) chemical substances
(toxins and venoms), (b) physical factors (mechanical trauma
and high or low temperatures), (c) endogenous mediators
(tissue protease and cationic proteins derived from eosinophils
and neutrophils), and (d) immune mechanisms that can be
IgE-dependent or IgE-independent.
IgE-dependent release is caused when allergens bind IgE
antibodies expressed by both mast cells and basophils.
Although mast cells reside in tissue and basophils typically
in blood, histamine can be released from either cell type.
Conversely, since negligible amounts of tryptase are present
in basophils, increased blood tryptase levels selectively indi-
cate mast cell activation. Blood tryptase levels generally cor-
relate with the clinical severity of the reaction. However, the
route of allergen exposure appears to be able to influence
tryptase levels, possibly related to the subtype of mast cell
the allergen first encounters. Mast cells that predominate in the
lungs and intestinal mucosa contain much less tryptase per cell
than those in connective tissues. Thus, tryptase levels may
correlate poorly in food anaphylaxis for example.
Physical factors such as high and low temperatures and
some drugs, for instance opioids, are thought to be able to
directly determine mast cell and basophil degranulation with a
mechanism independent from immune system involvement. It
must be emphasized, however, that diverging conclusions
exist on this issue in the literature. Whereas some studies have
demonstrated that rapid vancomycin infusion was accompa-
nied by a significant increase in plasma histamine without an
increase in plasma tryptase values, other investigations con-
cluded that tryptase is released with histamine during
nonimmunologic mast cell activation.
Mediators other than histamine and tryptase can be consid-
ered as clinical markers of mast cell activation. Leukotriene
C(4) and prostaglandin D(2) are both secreted by activated
mast cells. Although basophils do not produce prostaglandin
D(2), platelets, Langerhans cells and other antigen-presenting
cells contain prostaglandin D(2) synthase, and are able to
generate prostaglandin D(2). Thus, the source of prostaglan-
din D(2) measured in blood may be uncertain. Likewise,
leukotrienes are not uniquely produced by mast cells and their
determination in blood would therefore not distinguish mast
cell involvement from other inflammatory cells such as eosin-
ophils and basophils. Proteoglycans inside mast cells have
also been suggested as possible indicators of mast cell activa-
tion. While heparin is uniquely stored and released from mast
cells, currently, there is no practical assay of sufficient speci-
ficity and sensibility. Cathepsin G is also present in human
neutrophils. Mast cell carboxypeptidase and chymase are
potential markers for mast cell involvement, but thus far no
assays of adequate sensitivity and specificity for use with
biologic specimens have been developed [49–51].
Diagnosis of fatal reactions to contrast agents
in the forensic setting
Anaphylaxis is an acute, life-threatening systemic reaction with
varied mechanisms, clinical presentations, and severity that re-
sults from the sudden, systemic release of mediators from mast
cells and basophils. Diagnosis is based on suggestive clinical
symptoms after exposure to potential triggering agents or events.
Clinical diagnoses may be supported by laboratory investiga-
tions. Currently, histamine and β-tryptase are the classic labora-
tory parameters available for routine analyses.
Increased serum β-tryptase levels often correlate with in-
creased histamine concentrations, though imperfect interrelations
may be observed since β-tryptase diffuses through tissues more
slowly than histamine, presumably because of its association
with the macromolecular protease/proteoglycan complex.
During insect sting-induced anaphylactic hypotension, β-
tryptase levels are at their max 15 to 120 min after the sting,
whereas histamine peaks at approximately 5–10 min after symp-
tom onset and decline to the baseline within 60 min as a result of
rapid metabolism by N-methyltransferase and diamine oxydase.
Peak β-tryptase levels decline with a half-life of 1.5 to 2.5 h, and
β-tryptase levels may remain elevated for up to 5 h.
The practical consequence of the differing kinetics of hista-
mine and β-tryptase appearance and elimination from blood is
that samples for histamine determinationmust be obtainedwithin
15 min of episode onset, which might only be possible in a small
proportion of reactions, precluded in most circumstances when
reactions occur outside the hospital. Conversely, blood samples
for β-tryptase measurement can be obtained up to several hours
after the reaction begins, depending on its severity.
Although elevated serum β-tryptase concentrations sup-
port the existence of mast cell activation and hypersensitivity
reactions, failure to document its elevation does not refute this
diagnosis. Indeed, β-tryptase has been found to be within the
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normal range in asthmatic deaths. In addition, some cases of
clinically diagnosed hypersensitivity reactions to orally
ingested food allergens fail to show elevatedβ-tryptase levels,
though abundant amounts of IgE against the ingested allergen
can be detected. These findings would suggest that food
allergies might not be dependent on mast cell activation and
result in more basophil than mast cell activation [49, 51, 52].
Furthermore, besides cases of hypersensitivity reactions,
elevated β-tryptase levels have been identified in both serum
and postmortem serum in salicylate overdose, crushing blunt
force trauma, coronary artery atherosclerosis with and without
myocardial infarction, drug-related (mostly heroin) deaths,
and sudden infant death syndrome. Indeed, mast cells, hista-
mine, and β-tryptase are currently thought to be involved in
the cascade of events potentially linking eroded or ruptured
coronary plaques, coronary spasms, acute thrombotic occlu-
sions, and myocardial infarction [52–58].
The identification of fatal anaphylaxis may be extremely
challenging in forensic pathology routine. Acute hypersensitiv-
ity reactions are uncommon though well-recognized causes of
sudden death. Diagnosis during postmortem examination may
not be considered unless it was previously suspected based on
anamnesis, circumstances, or available medical information.
Factors that suggest allergic hypersensitivity reactions include
an immediately preceding challenge with an allergen known to
cause reactions, clinical features consistent with or suggesting
hypersensitivity reactions, a previous history of reactions to
similar or cross-reactive allergens, specific IgE antibodies to the
allergen thought to have caused the reaction, as well as mea-
surable products of mast cell activation and degranulation.
Unfortunately, most forensic cases have incomplete,
unreliable, or absent medical records when bodies are admitted
to the mortuary for medicolegal investigations. Additionally,
macroscopic and microscopic findings may be absent, leading
to the conclusion that the diagnosis of fatal anaphylaxis in the
forensic setting often relies exclusively on circumstantial evi-
dence when available and the exclusion of other potential causes
of death after all postmortem investigations.
Autopsy should be carried out as soon as possible when
death from acute hypersensitivity reactions is suspected.
Due to its short half-life of minutes, histamine can only be
detected in blood for a short period of time. Furthermore, hista-
mine is not stored exclusively in mast cells but also in basophils.
For this reason, histamine measured in postmortem serum is
most likely released from basophils during hemolysis.
Histamine is partlymetabolized toN-methyl-histamine and
excreted in urine. Urinary measurement of N -methyl-hista-
mine may be useful in living subjects after hypersensitivity
reactions since it is detectable up to 24 h after an episode, with
a significant peak within the first 3 h. However, genitourinary
bacteria may be capable of converting histidine to histamine
and falsely elevating urinary levels of histamine and its me-
tabolites. Hence, urine N -methyl-histamine measurements are
not reliable after death, while urinary samples obtained im-
mediately prior to death or immediately postmortem could be
useful for laboratory assays.
Markedly increased concentrations of β-tryptase in post-
mortem serum have been reported by several authors who
examined cases of sudden death in individuals who may have
died in the course of hypersensitivity reactions. According to
some observations, β-tryptase levels can be assessed in post-
mortem serum even days after death. Nevertheless, other
authors evaluate postmortem serum β-tryptase concentrations
carefully and claim that results on β-tryptase levels in post-
mortem samples may not be relied upon to the same degree as
in clinical examination mainly because of decompositional
changes. Moreover, as stated above, increased levels of post-
mortem serum β-tryptase can be frequently observed in sub-
jects with causes of death unrelated to hypersensitivity reac-
tions. In addition, due to decompositional changes involving
organs, tissues, and biological fluids, the main laboratory
procedures currently applied on samples obtained from living
individuals after hypersensitivity reactions are not necessarily
or extensively applicable to samples collected during autopsy.
Indeed, the concentration and stability of many analytes may
be modified under the effects of different thanatological pro-
cesses that may cause cytolysis and chemical molecule deg-
radation even immediately after death. Biochemical or immu-
nological assays are therefore not necessarily reliable when
performed on samples obtained postmortem.
This leads to the conclusion that postmortem straightfor-
ward diagnoses of fatal hypersensitivity reactions cannot be
exclusively based on β-tryptase determination alone.
Total and specific IgE may be measured in postmortem
serum. Even at average room temperature, the total amount of
IgE is considered relatively stable after death. However, high
titers of total IgE only provide information on atopic disposi-
tion whereas high titers of allergen-specific IgE indicate the
degree of sensitization to a particular allergen and confirm that
an IgE-mediated event has occurred, thereby not proving
death preceded by acute hypersensitivity reactions. Total IgE
may be elevated in many atopic individuals. Additionally,
some people with atopy may not display any detectable IgE
elevation, as some allergens may not proceed through an IgE
pathway to activate a response. Thus, relatively high titers of
IgE, specific for a given allergen, may not cause generalized
IgE elevations beyond clinical reference ranges. Moreover,
similar to β-tryptase, elevation of total IgE has been reported
in association with trauma and other conditions with a signif-
icant inflammatory component. Furthermore, total IgE levels
tend to rise with prolonged survival. Lastly, total IgE may be
elevated in other nonatopic conditions, including parasitic and
fungal infections. If the identity of the allergen causing fatal
hypersensitivity reaction is known or suspected, a specific IgE
assay for the allergen may be pursued to assess reactivity,
ostensibly providing a more specificmeans of diagnosing fatal
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anaphylaxis. Hence, an increase in IgE alone cannot prove
death by acute hypersensitivity reactions.
Finally, the forensic use of postmortem serum chymase
levels has been tested, at present, exclusively in one study.
This found a significant, positive correlation between tryptase
and chymase levels, thus suggesting that measurements of
mast cell-specific chymase levels could be an additional tool
for the postmortem diagnosis of hypersensitivity reactions
characterized by mast cell activation [59–66].
Laboratory investigations that can be performed in cases of
fatal adverse reactions to contrast material are summarized in
Table 1.
Conclusions
Adverse reactions to drugs and contrast material are relatively
frequent in clinical practice. Themost common are predictable
and dose-dependent. True allergies to contrast material con-
stitute a minority of these, with fatal cases being extremely
rare. With increased utilization of specialized investigations
with contrast medium administration, the likelihood of en-
countering subjects who experience life-threatening, adverse
reactions has also significantly increased over the years.
Though fatal cases do not necessarily imply medical malprac-
tice, physicians and radiologists may be involved in cases of
medical negligence with medicolegal autopsies requested by
the inquiring authorities. Therefore, forensic pathologists
must, at all times, be aware of the possible effects related to
contrast material utilization, underlying pathophysiological
mechanisms and diagnostic tools. As stated above, fatal cases
following contrast material administration are rare.
Unfortunately, some laboratory analyses are not readily avail-
able in all the facilities where postmortem examinations are
performed. Additionally, some analyses are not integrated in
routine autopsy investigations in most medicolegal centers.
Further collaborations involving laboratories and medicolegal
centers worldwide would thereby allow data pertaining to fatal
cases to be collected and centralized with the aim of exchang-
ing information internationally and improving the diagnostic
potential in the forensic field.
Not only iodinated contrast media but also gadolinium-
based contrast agents, ultrasound contrast material, and con-
trast media used in ophthalmic surgery are able to induce life-
threatening and potentially fatal adverse reactions. These can
be initiated by specific immunologic or nonimmunologic
mechanisms and may be either immediate or delayed. An
IgE-mediated, allergic mechanism may be one of the possible
mechanisms responsible for immediate reactions to
radiocontrast agents, at least in a portion of patients, though
several clinical observations favor a nonallergic mechanism in
some of these cases. Likewise, the role of IgE in MRI contrast
material reactions has been suggested in a portion of patients, Ta
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along with an IgE-independent mechanism in other individ-
uals. Despite advanced research focusing on the pathogenesis
of allergic and nonallergic reactions related to contrast media
utilization, a thorough understanding of the mechanisms in-
volved in each case continues to elude.
Mast cells and basophils are the primary effector cells of
immediate hypersensitivity reactions in humans. β-tryptase is
the principal protease in all mast cells, although basophils
contain trace amounts. Histamine found in the plasma of
living individuals can be released from either cell type where-
as histamine in postmortem serum is most likely from baso-
phils following hemolysis occurring after death. Negligible
amounts of β-tryptase are stored in basophils, and markedly
increased β-tryptase levels in serum and postmortem serum
indicate mast cell activation. However, increased concentra-
tions of postmortem serumβ-tryptase may also be observed in
situations with causes of death unrelated to allergic reactions.
Total and specific IgEmay bemeasured in postmortem serum.
However, increases in total and allergen-specific IgE cannot
prove death by acute hypersensitivity reactions. This leads to
the conclusion that the diagnosis of fatal adverse reactions to
contrast material in the forensic setting can only be formulated
based on consistent, circumstantial evidence after having ex-
cluded other potential causes of death.
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